Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70675 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Gaurav Joshi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Hemoglobinopathies. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, V Foundation for Cancer Research, Edward P. Evans Foundation.
Abstract (Originalsprache)
Gene therapy is revolutionizing treatment paradigms for inherited haematological and immunological conditions. Recent successes, including the United States Food and Drug Administration (FDA) approval of gene therapy products for sickle cell disease and beta‐thalassaemia, highlight the translational path of gene therapies for erythroid‐specific disorders. In contrast, gene therapy development for other inherited erythroid disorders remains largely preclinical. Here, we examine the emerging landscape of gene therapies for inherited non‐haemoglobinopathy erythroid disorders, focusing on the status of gene therapies for Diamond–Blackfan anaemia (DBA), pyruvate kinase deficiency (PKD), X‐linked sideroblastic anaemia (XLSA), congenital erythropoietic porphyria (CEP) and congenital dyserythropoietic anaemia (CDA). We discuss the latest cellular engineering approaches being applied to developing therapies for these erythroid disorders and evolving strategies for conditioning and engraftment of modified cells. Despite the rarity of these disorders individually, several convergent biological and translational themes have emerged. Leveraging shared insights across diseases may accelerate clinical translation and broaden the curative potential of gene therapy for inherited erythroid disorders beyond the haemoglobinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Pediatrics, Children's Medical Center, Dallas, Texas, USA.
- Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, USA.
ORCID-Profile: Gaurav Joshi, Nandakumar Natarajan, Richard A Voit
Förderung
- NCI NIH HHS
- V Foundation for Cancer Research
- Edward P. Evans Foundation
- Alex's Lemonade Stand Foundation for Childhood Cancer
- Cancer Prevention and Research Institute of Texas
- National Cancer Institute
Zitieren
APA
Joshi, G., Natarajan, N., Dickerson, K. E., & Voit, R. A. (2026). Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies. British Journal of Haematology. https://doi.org/10.1111/bjh.70675
Vancouver
Joshi G, Natarajan N, Dickerson KE, Voit RA. Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies. British Journal of Haematology. 2026. doi:10.1111/bjh.70675
BibTeX
@article{Joshi2026,
author = {Joshi, Gaurav and Natarajan, Nandakumar and Dickerson, Kathryn E and Voit, Richard A},
title = {Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70675}
}
EUVIMED